Spasmolytic therapy for primary dysmenorrhea
https://doi.org/10.21518/2079-701X-2018-13-180-184
Abstract
Purpose of the study. Perform a brief review of the published works devoted to the evaluation of the effectiveness and safety of drotaverine hydrochloride in the treatment of abdominal cramping caused by primary dysmenorrhea, and an analysis of the use of obtained data in the clinical obstetrician-gynecologist practice.
Materials and methods. The authors performed PubMed searches to find foreign and domestic articles using the keywords “dysmenorrhea”, “spasmolytic therapy”, “drotaverine”, “spasm”, “pain”. The analysis of the clinical studies showed the effectiveness of spasmolytic therapy of primary dysmenorrhea with drotaverin hydrochloride.
Conclusion. Drotaverine hydrochloride can be recommended as an effective and safe first-choice drug to treat primary dysmenorrhea.
About the Author
N. V. Kulagina
Mechnikov North-Western State Medical University of the Ministry of Health of Russia
Russian Federation
St.Petersburg
Russian Federation
St.Petersburg
References
1. Yakushevskaya OV, Revazova ZV. Microdose oral contraceptives in the therapy of dysmenorrhea. RMJ, 2014, 22 (1): 41-44.
2. Sasunova RA, Mezhevitinova EA. Contemporary views on the therapy of primary dysmenorrhea. Ginekologiya, 2009, 1: 60-62.
3. Harel Z. Dysmenorhea in adolescents and young adults an update on pharmacological treatments and management strategies. Expert Opinion on Pharmacotherapy, 2012, 13(15): 2157-2170.
4. Ju H, Jon es M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiologic Reviews, 2014, 36: 104-113.
5. Iacovides S, Avidon I, Bentley A et al. Reduc ed quality of life when experiencing menstrual pain in women with primary dysmenorrhea. Acta Obstet Gynecol Scand, 2014, 93(2): 213-217.
6. Gagua T, Tkeshelashvili B, Gagua D et al. Assessment of anxiety and depression in adolescents with primar y dysmenorrhea: A casecontrol study. J PediatrAdolesc Gyn ecol, 2013, 26(6) : 350-354.
7. Jobava EM, Mandrykina ZhA, Loginova KB, Dobrokhotova YuE. Dysmenorrhea. Etiopathogenesis, differential diagnosis and therapy in the modern obstetrician-gynecologist practice. RMJ. Akusherstvo i Ginekologiya, 2012, 1: 28-34
8. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol, 2012, 119(6): 1143–1150.
9. Nesterovskaya IV, Osipova AA. Noncontraceptive effects of hormonal contraceptives. Part 1. Dysmenorrhea, endometriosis, dysfunctional uterine bleeding. Akusherstvo, Ginekologiya i Reproduktsiya, 2008, 6: 11-14.
10. Kuznetsova IV. Problems of adolescence: when is it worth intervening? StatusPraesens. Ginekologiya, Akusherstvo, Besplodnyy Brak, 2018, 2 (45): 87-92.
11. Vozovik AV, Bazhukova NN. Dysmenorrhea in teenagers. Reproductive health of children and adolescents, 2008, 5: 40-42.
12. Tikhomirov AL, Yudina TA. Pathogenetic substantiation of hormonal treatment of primary dysmenorrhea. Reproduktivnoe Zdorovye Detey i Podrostkov, 2012, 5: 20-24.
13. Debski R, Niemiec T, Mazurec M, Debska M. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhea protocol DOROTA. Ginecol, Pol, 2007, 78: 933-938.
14. Jobava EM, Loginova KB. Dysmenorrhea. A modern view of etiopathogenesis and therapy in the obstetrician-gynecologist practice. Akusherstvo i Ginekologiya, 2014, 11: 23-28.
15. Elizavetina GA, Minushkin ON. Rational choice of antispasmodics for relief of abdominal pain. Consilium medicum, 2011, 8: 57-60.
16. Jamberardino MA. Visceral pain. International Association for the Study of Pain, update of clinical information on pain, 2005, XIII (6): 1-6. Available at: http://www.iasppain. org. It was accessed in December 2011.
17. Tar A, Singer J. Safety profile of NO-SPA®. Orvosi Hetilap, 2002, 143: 559-562.
18. Cherkasova NYu, Fomina AV, Filippova OV. Algorithm for the choice of therapy to treat dysmenorrhea as part of patient counseling at the pharmacy counter. Pharmateca, 2013, 6: 38-43.
19. Unanyan AL. Opportunities and prospects for the use of original drotaverine in dysmenorrhea: international study results. Akusherstvo i Ginekologiya, 2015, 1: 116-123.
20. Pareek A, Chandurkar NB, Patil RT, Agrawal SN, Uday RB, Tambe SG. Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized comparative study with aceclofenac. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2010, 152(1): 86-90.
Review
For citations:
Kulagina NV. Spasmolytic therapy for primary dysmenorrhea. Meditsinskiy sovet = Medical Council. 2018;(13):180-184. (In Russ.) https://doi.org/10.21518/2079-701X-2018-13-180-184
Views:
1032
Email this article 